| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Regencell Bioscience Holdings Limited$11.08
+0.39 (+3.71%)
Market Cap
12.76 B
EPS
-0.01
P/E Ratio
-
Value Trade
2.29 M
-2.68 %
Week
-9.54 %
1 Month
-23.05 %
3 Month
107.06 %
6 Month
8,070 %
5 Year
8,070 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
261.68 K
52 Week Range
9.39 - 83.60
% held by Insiders
88.68 %
% held by Institutions
0.13 %
Enterprise Value
12.76 B
Total Shares
494.49 M
Short %
4.38 %
Float Shares
17.80 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RGC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Regencell Bioscience Holdings Limited (RGC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
RGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RGC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RGC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RGCRegencell Bioscience Holdings Limited Announces Closing of Registered Direct Offering of Ordinary Shares
Regencell Bioscience Holdings Limited has successfully completed a registered direct offering of approximately $20 million, primarily led by a substantial investment from a new institutional investor. The offering involved the sale of 985,222 ordinary shares at a purchase price of $20.30 per share. This capital infusion is expected to enhance the company's research and commercialization efforts, particularly in Traditional Chinese Medicine for neurocognitive disorders. The offering was executed under a previously filed shelf registration statement with the SEC.
Read more →RGCRegencell Bioscience Holdings Limited Announces Registered Direct Offering of Ordinary Shares
Regencell Bioscience Holdings Limited has announced a registered direct offering of approximately 985,222 ordinary shares at a price of $20.30 per share, totaling an expected gross proceeds of $20 million. This financing is led by a new institutional investor and is set to close on May 20, 2026, subject to customary conditions. The funds will support the company's initiatives in developing traditional Chinese medicine therapies for neurocognitive disorders, such as ADHD and autism. The offering is pursuant to an effective shelf registration statement filed with the SEC.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2026 Management Financial Results
Regencell Bioscience Holdings Limited reported its unaudited financial results for the six months ending December 31, 2025. The company experienced a significant increase in net loss, which went up by 187% compared to the same period the previous year. Total operating expenses also saw a sharp rise of 170%, primarily driven by a substantial increase in administrative costs. Additionally, the company's total assets decreased markedly, reflecting a challenging financial environment.
Read more →RGCRegencell Bioscience Holdings Limited Announces At-the-Market Offering of Ordinary Shares
Regencell Bioscience Holdings Limited has announced the initiation of an at-the-market offering of ordinary shares, which may raise up to $500 million. The offering is facilitated through a sales agreement with Univest Securities, LLC as the sales agent. The company intends to use the proceeds primarily for working capital and general corporate purposes. The registration for the offering has been filed with the U.S. SEC, and prospective investors are encouraged to review the relevant prospectus for more details.
Read more →RGCFORM OF Fifth EXTENSION OF letter of Lock-Up Undertaking Date: From: (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this forth extension of the letter of lock-up und
Regencell Bioscience Holdings Limited has announced the fifth extension of a lock-up undertaking, extending the lock-up period for an additional twelve months until April 20, 2027. During this extended period, the option holder is allowed to transfer a specified percentage of vested options. The agreement will be governed by the laws of New York. No significant changes or developments affecting the company have been reported alongside this extension.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results
Regencell Bioscience Holdings Limited has released its unaudited financial results for the first half of 2025, reflecting continued challenges. The company reported a net loss of $1,853,613, a slight improvement from a loss of $2,185,893 in the same period a year earlier. Total assets decreased to $7,479,191 from $8,438,211, while total operating expenses also declined, indicating cost management efforts. Despite these adjustments, the losses indicate ongoing financial struggles for the company.
Read more →RGCRegencell Bioscience Holdings Limited Announces the Forward Stock Split is Effected
Regencell Bioscience Holdings Limited has announced a 38-for-one forward stock split, granting shareholders 37 additional shares for every share they hold on the record date. There will be no changes to the company's name, CUSIP, or trading symbol, and no action is required by shareholders to receive their additional shares. The company's strategic focus remains on the research and development of traditional Chinese medicine for treating neurocognitive disorders, such as ADHD and Autism Spectrum Disorder.
Read more →RGCRegencell Bioscience Holdings Limited Announces Forward Stock Split
Regencell Bioscience Holdings Limited has announced a 38-for-one forward stock split approved by its board of directors. Shareholders of record as of June 12, 2025, will receive 37 additional shares for each share held. The stock split aims to enhance liquidity and make shares more accessible to investors. Following the split, trading is expected to resume at market open on June 16, 2025, with no changes to the company's name or trading symbol.
Read more →RGCFORM OF FORTH EXTENSION OF LETTER OF LOCK-UP UNDERTAKING Date: From: (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this forth extension of the letter of lock-up und
Regencell Bioscience Holdings Limited has announced a fourth extension of a lock-up undertaking for a period of 15 months, extending the agreement until April 20, 2026. This extension involves an agreement between the Optionee and the Company, ensuring compliance under New York law for interpretation and enforcement. No significant positive or negative events were noted beyond the extension itself.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2024 Financial Results
Regencell Bioscience Holdings Limited announced its financial results for the first half of 2024, revealing a significant decrease in operating expenses by approximately 33%, totaling around $2.3 million. The company reported a net loss of approximately $2.2 million, a decrease of 34% from the previous year. Cash reserves improved notably, with an increase from $1.6 million in June 2023 to approximately $4.8 million as of December 31, 2023. The decrease in operating expenses was largely driven by lower costs in research and development and general administration.
Read more →RGCFORM OF LETTER OF LOCK-UP UNDERTAKING Date: From: (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this third extension of letter of lock-up undertaking (this " Third
Regencell Bioscience Holdings Limited has announced a third extension of a lock-up undertaking, extending the period during which certain options and shares cannot be sold. The extension will last for an additional twelve months, effective until January 20, 2025. This extension reinforces the company's efforts to maintain market stability and manage share distribution following their initial public offering. The agreement is governed by New York laws, ensuring consistency in interpretation and enforcement.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2023 Management Financial Results
Regencell Bioscience Holdings Limited revealed its unaudited financial results for the first half of 2023, reporting a net loss of $3,315,240. Despite a slight decrease in losses compared to the previous year, the company continues to incur high operating expenses. Regencell focuses on developing and launching Traditional Chinese Medicine (TCM) formulae for neurocognitive disorders. However, the absence of comprehensive clinical trial data poses a challenge for broader acceptance of their treatments.
Read more →RGCSECOND EXTENSION OF letter of Lock-Up Undertaking Date: ____________________ From: ____________________ (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this second ex
Regencell Bioscience Holdings Limited has announced a second extension of its lock-up undertaking agreement. The optionee has agreed to extend the lock-up period for an additional six months, which will now last until January 20, 2024. This extension aims to provide stability and prevent the premature sale of shares, thus supporting shareholder confidence post-IPO. The terms are governed by New York law.
Read more →RGCletter of Lock-Up Undertaking Date: __________________ From: __________________ (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this letter (this " Letter ") to (i) a
Regencell Bioscience Holdings Limited issued a letter of Lock-Up Undertaking, which includes an extension of the lock-up period for an additional six months. This extension follows an agreement allowing the purchase of ordinary shares by an Optionee. The arrangement prevents the sale or transfer of options, which may contribute to stability in the company's shareholder base. The agreement is governed by New York law, adding a layer of legal oversight.
Read more →RGCRegencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial - The Sik-Kee Au TCM Brain Theory Assessment for ADHD and ASD (" SKATBT-A 3 "), w
Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial HONG KONG, September 12, 2022--(Business Wire)--Regencell Bioscience Holdings Limited (Nasdaq: RGC) ("Regencell") today announced its inte
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2022 Management Financial Results
Regencell Bioscience Holdings Limited Announces First Half 2022 Management Financial Results HONG KONG, June 2, 2022 - Regencell Bioscience Limited (Nasdaq: RGC) (the "Company"), today announced its unaudited interim financial results for the six months ended December 31, 202
Read more →RGCRegencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19 TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Tre
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period Results of EARTH efficacy trial EARTH Eff
Read more →RGCFORM OF LETTER OF LOCK-UP UNDERTAKING Date
FORM OF LETTER OF LOCK-UP __________________ (the "Optionee") Pursuant to an agreement of option to purchase ordinary share of Regencell Bioscience Holdings Limited dated June 9, 2021, the Company granted to the Optionee certain options (the "Options") to purchase ordinary sh
Read more →RGCRegencell Bioscience's Investigational Liquid-Formula RGC-COV19 TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Effica
Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial Hong Kong, February 17, 2022 - Regencell Bioscien
Read more →RGCRegencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors Hong Kong
Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors Kong, December 13, 2021 - Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and co
Read more →RGCJOINT VENTURE AGREEMENT THIS JOINT VENTURE AGREEMENT (the " Agreement ") is made and entered and effective as of
JOINT VENTURE AGREEMENT (the "Agreement") is made and entered and effective as of September 2, 2021, a "Party" and collectively the "Parties"). AGREEMENT WITNESSES as follows:- " Board " Board of directors of the Company; " Control " In the case of a company, the possession,
Read more →RGCRegencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option HONG KONG, August 20, 2021--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, de
Read more →RGCRegencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering Hong Kong
Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering Kong, July 15, 2021 - Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development
Read more →Competitive Position
How RGC ranks across every disease it competes inCompetitive Position is a premium feature
See how RGC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial